Histologically or cytologically confirmed locally advanced or metastatic NSCLC
Without epidermal growth factor receptor (EGFR) sensitizing mutation, and anaplastic lymphoma kinase (ALK) fusion gene.
Provide a tumor tissue sample.
At least one measurable lesion as assessed by the investigator according to RECIST v1.1.
ECOG performance status of 0 or 1.
Life expectancy ≥ 12 weeks.
Adequate bone marrow, liver, kidney, and coagulation function.
Male and female participants must agree to use highly effective methods of contraception during the specified period of the study.
You may not be if
Histologically or cytologically confirmed co-existing small cell lung cancer, neuroendocrine carcinoma, or carcinosarcoma components.
Participants with known metastases to meninges, brainstem metastases, metastases to spinal cord and/or compression, or active metastases to central nervous system (CNS).
Uncontrolled systemic disease as judged by the investigator.
Presence of uncontrolled, clinically symptomatic, or requiring repeated drainage pleural effusion, pericardial effusion, or ascites.
Presence of other moderate to severe lung disorders.
History of haemorrhagic diathesis or coagulopathy and/or clinically significant bleeding symptoms or risks.
Previous or co-existing gastrointestinal diseases, surgery, and wound healing complications.
Active hepatitis b or hepatitis c or co-infection with HBV and HCV.
Known history of allogeneic organ transplantation or hematopoietic stem cell transplantation.
Known hypersensitivity to the study drug or any of its components.
Pregnant or lactating women.
Clareo Health | SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer
